We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
Sponsor content
323 result(s) found, displaying 51 to 60
-
Prescription medicine decision summaryTruqap (capivasertib), in combination with fulvestrant, is approved for the treatment of adult patients with locally advanced or metastatic breast cancer.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for Pulmicort Respules Budesonide Suspension for Inhalation 2ml: 0.5mg.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for Pulmicort Respules Budesonide Suspension for Inhalation 2ml: 1mg.
-
-
Prescription medicine decision summaryLokelma (sodium zirconium cyclosilicate hydrate) was approved for the treatment of hyperkalaemia in adult patients. Lokelma binds to potassium in the gut and is used to treat high levels of potassium in the blood.
-
Prescription medicine registrationActive ingredients: dapagliflozin propanediol monohydrate, sitagliptin phosphate monohydrate.
-
Designation or determinationProvisional determination
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for Pulmicort Respules budesonide 1 mg/2 mL.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for Pulmicort Respules budesonide 0.5 mg/2 mL.
-